WO1996000217A1 - Optically active quinolinecarboxylic acid derivative and process for producing the same - Google Patents
Optically active quinolinecarboxylic acid derivative and process for producing the same Download PDFInfo
- Publication number
- WO1996000217A1 WO1996000217A1 PCT/JP1995/001255 JP9501255W WO9600217A1 WO 1996000217 A1 WO1996000217 A1 WO 1996000217A1 JP 9501255 W JP9501255 W JP 9501255W WO 9600217 A1 WO9600217 A1 WO 9600217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- halogen
- formula
- alkyl
- optically active
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Definitions
- the present invention relates to an intermediate useful for producing an optically active thiazetoquinoline carboxylic acid derivative (eg, JP-A-3-218383) useful as an antibacterial agent, and a method for producing the intermediate.
- an optically active thiazetoquinoline carboxylic acid derivative eg, JP-A-3-218383
- the present inventors have proposed an optically active 6-fluoro-7-substituted-4-oxo-4H-4H- [1,3] which is an important intermediate for producing an optically active thiazetoquinolinecarboxylic acid derivative useful as an antibacterial agent.
- An object of the present invention is to provide an optically active alkyl 2- (1-cyclo (2-substituted) ethyl) thio 6-fluoro-7-substituted-4-acysiloxyquinoline-3-carboxylate.
- An object of the present invention is to provide a derivative and a method for producing the derivative. In the course of examining various production methods, the present inventors found that the 4- (2-substituted) ethyl) thio 6-fluoro-7-substituted-4-monohydroxyquinoline-3-carboxylate alkyl ester derivative had a 4-position.
- a chiral substituent is introduced into the thiol group, and the ethyl group at the 2-position is chlorinated with a gun. It has been found that it is possible to easily produce large amounts of alkyl 1-chloro (2-S exchanged) ethyl thio 6-fluoro-7-substituted-4-acyloxyquinoline-3-carboxylate derivatives. .
- the present invention relates to the following general formulas (Ia) and (Ib)
- R 1 is hydrogen, halogen, hydroxy, alkoxy, aryl Represents Roxy and Asiloxy.
- R 2 represents hydrogen, alkyl, alkoxy, amino or halogen.
- R 3 represents alkyl.
- R 4 represents a chiral acyl.
- X represents a halogen, a substituted or unsubstituted cyclic amino or phenyl. ] It is related with the optically active quinoline carboxylic acid derivative represented by these.
- R ' as Ha androgenic represented by R 2
- X for example, fluorine, chlorine, it is monkey in ⁇ Geru a bromine 0
- alkoxy represented by R 1 and R 2 straight-chain or branched-chain low alkoxy having a prime number of 14 is preferable, for example, methoxy, ethoxy, n-propoxy, di-novoxy, n-butoxy. , Isobutoxy, sec-butoxy, tert-butoxy and the like.
- the aryloxy represented by R 1 is preferably an aryl having 6 to 10 atoms, for example, phenyl, ⁇ -naphthyl or ⁇ -decyl which is unsubstituted or substituted by halogen or alkoxy. be able to. Examples of the halogen and alkoxy include those described above.
- the acyloxy represented by R ′ is preferably an acyl having 1 to 4 carbon atoms, and examples thereof include formyl, acetyl, propionyl, and petyryl.
- alkyl represented by R 8 and R 3 a linear or branched alkyl group having 1 to 4 carbon atoms is preferable, and examples thereof include methyl, tyl, ⁇ -butyl, isopropyl, ⁇ -butyl, and isobutyl. sec-butyl, tert-butyl and the like.
- any chiral acyl may be used as long as it has an asymmetric carbon, and a branched alkylcarbonyl, a branched aralkylcarbonyl, an amino acid residue and the like can be used. .
- an amino acid residue one having an amino group protected so as not to hinder the reaction is used.
- Such chiral acyls include, for example, 2-phenylpropionyl, 2-methoxy-2-phthylacetyl, 0-benzyllactoyl, N-benzyloxycarbonyl-D-phenylglycyl, N-benzylo Xycarbonyl-L-alanyl, N-benzoyl-L-prolyl, N-benzoyl-L-aralanyl, N-methoxycarbonyl-D-glycyl, 2-acetoxy-2-phenylphenylcetyl, 2- Methyl octane oil etc. can be obtained. Above all, those having an asymmetric compound at the 2-position, such as 2-phenyl-2-nitropropionyl and 2-methoxy-2-phenylacetyl Is preferred.
- the cyclic amino group represented by X is a 4- to 8-membered ring, and may further contain a nitrogen, oxygen or sulfur atom as a constituent atom.
- Examples of such cyclic amino include, for example, tozetidinyl, 1-pyrrolidinyl, piperidino, azepinyl, 1-azocinyl, 1-pirazuryl, 1-homopiperazinyl, 1-pyrrolinyl, morpholino, thiophorolino, 3,7-diazabicyclo [3.3.0] octa-1 (5) -en-3-yl, 4,7-diazspiro [2.5] octen-7-yl, 7-ami No-5-azaspiro [2.4] heptane-5-yl group.
- Cyclic amino groups may have one or more substituents, such as alkyl, hydroxyalkyl, aminoalkyl, acyl, amino, hydroxy or (5-methyl-2 -Oxo-1,3-dioxol-4-yl) methyl.
- the alkyl or acyl contained in such a substituent may be those described above. Particularly, substituted or unsubstituted pyrrolidinyl and piperazinyl are preferred.
- substituents may include amino, alkylamino, aminoalkyl, hydroxy, alkoxy or acyl.
- alkyl or alkoxy contained in such a substituent include those described above.
- acyl can be the same as those of the above-mentioned acyloxy.
- the present invention can be carried out, for example, by the following reaction formula to obtain optically active compounds [Ia] and [Ib] of the present invention.
- compound [III] is acylated in a suitable solvent in the presence of a suitable condensing agent.
- a suitable solvent for example, halogenated hydrocarbons such as methylene chloride and chloroform, aromatic hydrocarbons such as benzene and toluene, and hydrocarbons such as n-hexane can be used. it can.
- Chiral carvone As the acid or amino acid, those corresponding to can be used.
- 2-phenyl brobionic acid 0-methyl mandelic acid, 0-benzyl lactic acid, N-benzyloxycarbonyl-D-phenylglycine, N-benzyloxycarbonyl-L-alanine, N-benzoyl-L-pro Lin, N-benzoyl-L-alanine, N-methoxycarbonyl-D-glycine, 0-acetoxy-2-phenylphenolic acid, and 2-methyloctylic acid can be used.
- condensing agent examples include acetic anhydride, trifluoranhydride, dicyclohexyl carbodiimide (DCC), N-ethyl-N '-(3-dimethylaminopropyl) carbodiimide (BDC), and trifluoracetyl sulfide. Midazole, acetilui midabour, and the like can be used.
- the use 11 of the condensing agent and the carboxylic acid or amino acid is in an equimolar amount to an excess amount, preferably 1.0 to 2.5 mol, per 1 mol of [III].
- the reaction is usually carried out at a temperature between 1 78'C and the boiling point of the solvent, preferably between 0 and 50.
- the reaction time varies depending on [III] used, the type of carboxylic acid or amino acid, the type of solvent and the reaction temperature, but is usually 30 minutes to 48 hours.
- the compound [III] is acylated using a chiral carboxylic acid or a reactive derivative of an amino acid (eg, acid chloride or acid anhydride), it is carried out in a suitable solvent in the presence of a suitable base.
- an acid chloride the acid chloride of the above-mentioned carboxylic acid or amino acid can be used.
- anhydride an acid anhydride obtained from a chiral carboxylic acid or an amino acid or a mixed acid anhydride obtained from a chiral carboxylic acid or an amino acid and an alkyl chlorate can be used.
- the solvent those described above can be used.
- Organic bases such as sodium acetate, triethylamine, tripropylamine, viridin, succinimidona, a-pyrrolidonna sodium, lithium hydroxide, sodium bicarbonate, water
- An inorganic base such as sodium oxide can be used.
- the amount of the base and the acid chloride or the acid anhydride to be used is from equimolar to excess mol, preferably 1.0 to 2.5 mol, per 1 mol of [III].
- the reaction is usually, ⁇ 78 e Celsius to the boiling point of the solvent, preferably carried out at 0 'C ⁇ 50'C.
- the reaction time varies depending on the type of [III] used, the type of carboxylic acid or amino acid chloride or acid anhydride, the type of solvent and the reaction temperature, but is usually 30 minutes to 48 hours.
- the target compound [II] produced in this manner can be converted into a free base or an acid addition salt by known means, for example, by concentration, liquid conversion, phase transfer, solvent extraction, Simple purification can be performed by crystallization and chromatography.
- compound [II] is chlorinated to produce compound [1] which is a mixture of diastereomers.
- This chlorination reaction is performed using a chlorinating agent in a solvent inert to the reaction.
- a chlorinating agent for example, halogenated hydrocarbons such as chloroform, dichloromethane, carbon tetrachloride, hydrogen peroxides such as hexane, ethers such as dioxane, tetrahydrofuran and the like are used.
- the chlorinating agent N-chlorosuccinic acid imide, sulfuryl chloride or chlorine can be used.
- the chlorinating agent is used in an equivalent amount to an excess amount, preferably 1.0 to 5.0 equivalents, relative to compound [II].
- the reaction is usually performed at a temperature between 30'C and 100'C.
- the reaction time depends on the compound used (11), the chlorinating agent and the solvent. The time is usually 30 minutes to 24 hours, depending on the type and reaction temperature.
- the resulting mixture of the two diastereomeric esters can be easily converted to each diastereomer (Ia) and (Ib) by a method such as chromatography or fractional crystallization utilizing the difference in polarity or difference in solubility. Can be divided into two groups.
- Fractional crystallization is performed by dissolving a mixture of two diastereomeric esters in a suitable solvent and selectively precipitating only one diastereomer crystal by stirring, cooling, etc. be able to.
- a solvent for example, a solvent other than alcohol can be used.
- ethers such as getyl ether, diisopropyl ether, dibutyl pill ether, dioxane, tetrahydrofuran, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform, dichloromethane, and tetrachloride.
- the solvent may be a mixture of two or more of these solvents, and the purity may be increased by recrystallizing the obtained crystal from the above-mentioned solvent.
- Isomer is 6,7-difluoro-2- (1-chloro-1-fluoroethyl) thio-4-((R) -2-phenylpropionyl) oxyquinoline-3-ether Ethyl acid ester and 6,7-difluoro-2- (chloro-1-fluoroethyl) thio-4-((R) -2-methoxy-2-phenylacetoxy) quinoline-3-hydrorubon When it is an acid ethyl ester, diisopropyl ether is particularly preferred as a solvent for the fractionated crystals.
- the starting compound [III] can be produced by a known method (eg, W093 / 25532).
- optically active compounds ( Ia ) and (Ib) of the present invention are novel compounds, and are useful for the treatment of infections caused by gram-negative bacteria, intractable Pseudomonas aeruginosa infections and gram-induced bacterial infections. It is useful as an intermediate for the synthesis of an optically active thiazetoquinoline carboxylic acid derivative (W094 / 14819)
- the compound [Ib] of the present invention can be prepared by a known method (eg, published in WO93 / 2553 ⁇ ). ), The ring can be closed as follows to lead to an optically active compound [IVb] which is an important intermediate for producing a thiazetoquinoline carboxylic acid derivative having antibacterial activity.
- Non-protonic polar solvents such as ethers such as, ⁇ ⁇ , ⁇ ⁇ -dimethylformamide, ⁇ , ⁇ -dimethylacetamide, dimethyl sulfoxide, sulfolane, and mixtures thereof.
- Organic bases eg, sodium acetate, triethylamine, O Use can be made of tripropylamine, pyridine, succinimidonadium salt, monopyrrolidone sodium salt, etc., inorganic bases (eg, lithium hydroxide, sodium hydrogen carbonate, sodium hydroxide), etc.
- the 3 ⁇ 4 group is generally used in an amount of 1 to 10 equivalents based on [Ib].
- the reaction time varies depending on [Ib], the type of the base and the solvent, and the reaction temperature, but is usually 30 minutes to 180 hours.
- 6,40-Difluoro-2- (2-fluoroethyl) thio-4-hydroxyquinoline-3-hydroxyethyl ester 2.40 g and triethylamine 1.01 g are dissolved in 45 ml of black-mouthed form and cooled with ice. Under stirring, a solution prepared by dissolving 1.70 g of (R)-(-)-2-phenylpropionyl chloride in 5.0 ml of chloroform was slowly added dropwise. After completion of the dropwise addition, the mixture was stirred at room temperature for 5 hours.
- reaction solution was washed successively with an aqueous solution of sodium hydrogencarbonate, hydrochloric acid and saturated brine, dried over magnesium sulfate, and concentrated.
- the crystals were recrystallized again from about 15 ral of isobrovir ether and subjected to diastereomeric resolution to obtain crystals of 310 ⁇ .
- Quantification was performed under the same conditions using an HPLC column. d.e .: 50.1%
- the crystals were further recrystallized from 20 ml of a mixed (1: 1) solvent of isopropyl ether and ethyl acetate, and subjected to diastereomer separation to obtain 140 mg of crystals. Yield 53.81 ⁇ 2.
- Example 1 (2) Using the compound obtained in the above (1), 0.97 g of the target compound was obtained as colorless crystals in the same manner as in Example 1 (2). This crystal was recrystallized twice from isobrole to separate diastereomers. The proportion of diastereomers was analyzed by HPLC.
- Example 1 (2) Using 1.70 g of the compound obtained in the above (1), 1.34 g of the target compound was obtained in the same manner as in Example 1 (2). This crystal is isopropyl ether The crystals were recrystallized three times to separate the diastereomers.
- Existence ratio of Jiasutereo mer, MeCN as eluant: H 2 0: MeSO s H -80: 20: 0.1 have use of the other were analyzed by HPLC under the same conditions as in Example 4 (2).
- Example 1 using 2.43 g of 6,7-difluoro-mouth 2- (2-fluoroethyl) thio-4-hydroxyquinoline-3-ether ethyl ester and 1.75 g of 0-benzyl-lactyl lip 2.87 g of the desired compound was obtained in the same manner as in (1). 45-47'C
- Example 4 (2) The same method as in Example 1 (2) using the above (2.50 g of the compound obtained in U) Thus, 1.55 g of the target compound was obtained. This crystal was recrystallized three times from isopropyl ether to separate diastereomers. The diastereomer abundance was analyzed by HPLC under the same conditions as in Example 4 (2).
- Example 1 (2) Using 0.96 g of the compound obtained in the above (1), 0.64 g of the target compound was obtained in the same manner as in Example 1 (2). The crystals were recrystallized three times from a mixed solvent of isopropyl ether ethyl acetate to separate diastereomers.
- Example 2 Using 2.00 g of the compound obtained in (1) above, the target compound l.OOg was obtained in the same manner as in Example 1 (2). The crystals were recrystallized four times from acetone to separate diastereomers. The diastereomer abundance was analyzed by HPLC under the same conditions as in Example 4 (2).
- Example 1 2- (1-kuguchi-2-2-fluoroethyl) thio 6,6-difluoro-4-((R) -2-phenylpropionyl) oxyquinoline-3 obtained in (2) Acid ethyl ester Omg, triethylamine 90mg, water 6 A mixture of mg and tetrahydrofuran (THF) 3. Oml was heated and refluxed for 6 hours to react. After the completion of the reaction, the reaction solution was gradually returned to room temperature, and the mixture was stirred at room temperature for 1 hour. The crystals were thoroughly washed sequentially with THP, water, THF, and ether, and dried under vacuum to obtain 83 mg of the desired product. Yield 83.8%.
- THP tetrahydrofuran
- the compound obtained by the reaction was quantified by HPLC isomer for optical isomer separation.
- Example 2 2- (1-chloro-2--2-fluoroethyl) thio 6,6-difluoro-4-((R) 2-phenylpropionyl) oxyquinoline-3 obtained in (2) Ethyl rubonate And operate in the same manner as in Reference Example 1. I got a target.
- Example 3 4-[(R)-(N-benzyloxycarbonyl) -L-arael] oxy-2- (cyclo-2--2-fluoroethyl) thio 6,7-difluoroquino obtained in Example 3 (2)
- the target product was obtained in the same manner as in Reference Example 1 using phosphoric acid 3-ethyl rubonate.
- Example 9 2- (1-chloro-2-2-fluoroethyl) thio 6,7-difluor-4-((R) 2-methoxy-2-phenyl) acetoxyquinoline obtained in (2) The same procedure as in Reference Example 1 was carried out using 3-ethyl ethyl ester to obtain the desired product. Optical purity 97.1 ⁇
- an optically active 2- (1-hydroxy- (2-substituted) ethyl) thio 6-fluoro-7-substituted-4-acyloxyquinoline-3 monorububon is used.
- the acid alkyl ester derivatives [Ia] and [Ib) can be produced efficiently and in large quantities.
- the optically active compound [Ia] or [Ib] of the present invention is used as an intermediate, the optically active 6-fluoro-7-halogeno-1- (S ⁇ ) methyl-4-oxo is obtained efficiently and economically.
- -4H- [1,3] thiazeto [3,2-a] Quinolincarboxylic acid alkyl ester derivative can be produced, which is industrially advantageous.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95922744A EP0768303A4 (en) | 1994-06-27 | 1995-06-23 | OPTICALLY ACTIVE QUINOLINE-CARBOXYLIC ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6/144892 | 1994-06-27 | ||
| JP14489294 | 1994-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996000217A1 true WO1996000217A1 (en) | 1996-01-04 |
Family
ID=15372778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1995/001255 Ceased WO1996000217A1 (en) | 1994-06-27 | 1995-06-23 | Optically active quinolinecarboxylic acid derivative and process for producing the same |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP0768303A4 (ja) |
| WO (1) | WO1996000217A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03218383A (ja) * | 1989-11-17 | 1991-09-25 | Nippon Shinyaku Co Ltd | 光学活性キノリンカルボン酸誘導体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63107990A (ja) * | 1986-05-14 | 1988-05-12 | Nippon Shinyaku Co Ltd | キノリンカルボン酸誘導体 |
| AU6367690A (en) * | 1990-07-10 | 1992-05-21 | Hokuriku Pharmaceutical Co. Ltd. | Optically active thiazetoquinoline-3-carboxylic acid compound, method for preparation thereof, and a pharmaceutical composition comprising the same |
-
1995
- 1995-06-23 EP EP95922744A patent/EP0768303A4/en not_active Withdrawn
- 1995-06-23 WO PCT/JP1995/001255 patent/WO1996000217A1/ja not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03218383A (ja) * | 1989-11-17 | 1991-09-25 | Nippon Shinyaku Co Ltd | 光学活性キノリンカルボン酸誘導体 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP0768303A4 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0768303A1 (en) | 1997-04-16 |
| EP0768303A4 (en) | 1999-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4114754B2 (ja) | 1−置換−3−フルオロアルキルピラゾール−4−カルボン酸エステルの製造方法 | |
| EP3481200B1 (en) | Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides | |
| JP3771566B2 (ja) | 1−オキサセファロスポリン−7α−メトキシ−3−クロルメチル誘導体の製法 | |
| JP4667691B2 (ja) | ナプロキセンのニトロキシアルキルエステルの製造法 | |
| KR100309871B1 (ko) | (-)피리도벤즈옥사진 카르복실산 유도체의 제조방법 | |
| KR910000238B1 (ko) | 티아졸 유도체의 제조방법 | |
| WO1996000217A1 (en) | Optically active quinolinecarboxylic acid derivative and process for producing the same | |
| JP2000351776A (ja) | 光学活性ホモシステインチオラクトン塩の製造方法およびその中間体 | |
| JP2010077089A (ja) | ハロピラジンカルボキサミド化合物の製造方法 | |
| NO761352L (ja) | ||
| JPH09143173A (ja) | 光学活性な5,5−ジフェニル−2−オキサゾリジノン誘導体 | |
| KR100320772B1 (ko) | (s)-벤족사진 유도체의 제조방법 및 (r)-벤족사진 유도체의 라세미화 방법 | |
| JPWO1996000217A1 (ja) | 光学活性なキノリンカルボン酸誘導体及びその製造法 | |
| JPH0940692A (ja) | グリシン誘導体の製造方法 | |
| JP3011784B2 (ja) | 新規なピリジンスルホン酸エステル | |
| JP2000007609A (ja) | カルボン酸誘導体の製造法 | |
| JP4114185B2 (ja) | 光学活性アラニン誘導体の製造法及び有用原料化合物 | |
| JPH0859618A (ja) | 光学活性な1,4−ジヒドロピリジン化合物およびその製造法 | |
| KR20010073096A (ko) | 옥사졸 화합물의 제조방법 | |
| JPS61158962A (ja) | 1,4−ジヒドロピリジン誘導体の製造法 | |
| JPH03130280A (ja) | 4―アリールオキシ―1,3―ベンゾジオキソール類の製造方法 | |
| JP2987957B2 (ja) | 1,3−ジヒドロキシアセトン誘導体及びその製造方法 | |
| JPH07103129B2 (ja) | ペニシラン酸誘導体の改良された新規合成方法 | |
| KR890000523B1 (ko) | 세팔로스포린 유도체의 제조방법 | |
| JPH0812658A (ja) | シドノン類の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 765321 Date of ref document: 19961224 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1995922744 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1995922744 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1995922744 Country of ref document: EP |